Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 8/20 | 0.64 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.64 |
| ▸ | CCR2 | P41597 | 3/20 | 0.64 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.55 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | ITK | Q08881 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.48 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7296357 | 0.83 | ROCK2 (0.61) | ROCK2ROCK1CCR2ITKACHE | |
| SCHEMBL3319580 | 0.83 | ROCK2 (0.58) | ROCK2ROCK1CCR2ITKACHE | |
| SCHEMBL5409256 | 0.82 | ROCK2 (0.83) | ROCK2ROCK1CCR2KDM4E | |
| Hydrochloric Acid SCHEMBL5409061 | 0.81 | ROCK2 (0.82) | ROCK2ROCK1CCR2KDM4E | |
| SCHEMBL5405680 | 0.80 | ROCK2 (0.62) | ROCK2ROCK1CCR2ITKACHE | |
| SCHEMBL918426 | 0.78 | KDM4E (0.66) | ROCK2ROCK1CCR2ACHEKDM4E | |
| SCHEMBL7286870 | 0.78 | KDM4E (0.67) | ROCK2ROCK1CCR2ACHEKDM4E | |
| SCHEMBL923860 | 0.78 | LMNA (0.68) | ROCK2ROCK1CCR2ACHEKDM4E | |
| SCHEMBL5418874 | 0.78 | ROCK2 (0.63) | ROCK2ROCK1CCR2ITKACHE | |
| SCHEMBL224917 | 0.78 | ROCK2 (1.00) | ROCK2ROCK1CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132540-A1 | NON-PEPTIDIC NPY Y2 RECEPTOR INHIBITORS | CARRUTHERS NICHOLAS I | 2008-06-05 | — | — | US | disclosed |
| US-7317025-B2 | Non-peptidic NPY Y2 receptor inhibitors | JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, LLC (US) | 2008-01-08 | — | — | US | disclosed |
| WO-2005030754-A1 | INDOLE OR QUINOLINE DERIVATIVES AS NON-PEPTICID NPY Y2 RECEPTOR INHIBITORS USEFUL FOR THE TREATMENT OF ANXIOLYTIC AND DEPRESSIVE DISORDERS AND OBESITY | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-04-07 | — | — | WO | disclosed |
| US-20050070534-A1 | Non-peptidic NPY Y2 receptor inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132540-A1 | NON-PEPTIDIC NPY Y2 RECEPTOR INHIBITORS | NPY2R, NPY1R, NPY5R | ROCK2 342/4885ROCK1 565/4885CCR2 813/4885 |
| US-20050070534-A1 | Non-peptidic NPY Y2 receptor inhibitors | NPY2R, NPY1R, NPY5R | ROCK2 342/4885ROCK1 565/4885CCR2 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.